At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 341 enrolled
Drug / intervention
Ixekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab, Placebo, and 1 other intervention for Spondyloarthritis. Completed, enrolled 341 participants across 28 sites in 7 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial spondyloarthritis (rad-axSpA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpondyloarthritis
CountriesCzechia, Germany, Japan, Netherlands, South Korea, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMay 2016
Primary CompletionDec 2017
Study CompletionOct 2018
TodayJul 2026
First PostedMar 2, 2016
Enrollment StartMay 2, 2016
Primary CompletionDec 8, 2017
Study CompletionOct 17, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.3 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC
Adalimumabdrug
Administered SC